Table 1

Summary of changes from baseline in EORTC QLQ-C30 global QoL

dMMR/MSI-H population
Dostarlimab (n=53)Placebo (n=65)
Evaluable patients, n5164
Baseline score, mean (SD)66.7 (25.91)67.3 (23.93)
No. of patients at cycle 73948
Change from baseline, mean (SD)1.4 (23.33)−6.0 (26.12)
Improved, n (%)14 (35.9)12 (25.0)
Stable, n (%)15 (38.5)16 (33.3)
Worsened, n (%)10 (25.6)20 (41.7)
No. of patients at cycle 132714
Change from baseline, mean (SD)9.2 (17.30)−8.5 (15.86)
Improved, n (%)12 (44.4)2 (14.3)
Stable, n (%)12 (44.4)7 (50.0)
Worsened, n (%)3 (11.1)5 (35.7)
No. of patients at EOT2243
Change from baseline, mean (SD)3.0 (19.42)−11.1 (29.10)
Improved, n (%)4 (18.2)9 (20.9)
Stable, n (%)14 (63.6)13 (30.2)
Worsened, n (%)4 (18.2)21 (48.8)
  • dMMR, mismatch repair-deficient; EORTC, European Organisation for Research and Treatment of Cancer; EOT, end of treatment; MSI-H, microsatellite instability-high; QLQ-C30, Quality of Life Questionnaire Core 30; QoL, quality of life.